Cargando…
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577341/ https://www.ncbi.nlm.nih.gov/pubmed/37226446 http://dx.doi.org/10.3350/cmh.2023.0114 |